Compare
ICF International, Inc. vs Astrana Health, Inc. vs Onterris, Inc. vs Genpact Ltd
| Latest fiscal year | ICF International, Inc. ICFI | Astrana Health, Inc. ASTH | Onterris, Inc. ONT | Genpact Ltd G |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.87B | $3.18B | $830.54M | $5.08B |
| Revenue growth (YoY) | -7.3% | +56.4% | +19.3% | +6.6% |
| Gross margin | 37.2% (computed) | n/a | 40.3% (computed) | 36.0% |
| Operating margin | 7.8% | 2.5% | 1.4% | 14.8% |
| Net margin | 4.9% | 0.7% | -0.1% | 10.9% |
| Net income | $91.59M | $22.49M | -$843.0K | $552.49M |
| EPS (Diluted) | $4.95 | $0.46 | -$0.14 | $3.13 |
| Operating cash flow | $141.87M | $114.60M | $107.48M | $812.86M |
| Free cash flow | $120.21M | $104.49M | $91.16M | $734.65M |
| Cash & equivalents | $5.30M | $429.47M | $11.22M | $853.84M |
| Total assets | $2.05B | $2.22B | $981.30M | $5.84B |
| Total liabilities | $1.02B | $1.66B | $530.12M | $3.29B |
| Shareholders' equity | $1.03B | $779.29M | $451.18M | $2.55B |
| Return on year-end equity | 8.9% | 2.9% | -0.2% | 21.7% |
| Shares outstanding | 18.25M | 48.89M | 35.93M | 170.34M |
Revenue, most recent five fiscal years
| Fiscal year | ICF International, Inc. | Astrana Health, Inc. | Onterris, Inc. | Genpact Ltd |
|---|---|---|---|---|
| Latest | $1.87B Ended 2025-12-31 | $3.18B Ended 2025-12-31 | $830.54M Ended 2025-12-31 | $5.08B Ended 2025-12-31 |
| 1 year earlier | $2.02B Ended 2024-12-31 | $2.03B Ended 2024-12-31 | $696.39M Ended 2024-12-31 | $4.77B Ended 2024-12-31 |
| 2 years earlier | $1.96B Ended 2023-12-31 | $1.39B Ended 2023-12-31 | $624.21M Ended 2023-12-31 | $4.48B Ended 2023-12-31 |
| 3 years earlier | $1.78B Ended 2022-12-31 | $1.14B Ended 2022-12-31 | $544.42M Ended 2022-12-31 | $4.37B Ended 2022-12-31 |
| 4 years earlier | $1.55B Ended 2021-12-31 | $773.91M Ended 2021-12-31 | $546.41M Ended 2021-12-31 | $4.02B Ended 2021-12-31 |